eMBR Genomics Partners with Axio BioPharma to Manufacture and Distribute Proprietary MKLP1 Pro Antibodies

Madison, WI – January 06, 2024 – In a milestone for cellular research, eMBR Genomics and Axio BioPharma announce the first commercial availability of MKLP1 Pro™ antibodies, KIF23 gene – the same tools used by the world’s leading Midbody Remnants (MBRs) researchers. This strategic partnership combines eMBR's innovation in detecting MBRs with Axio BioPharma's superior manufacturing and global distribution network, making these proprietary antibodies accessible to scientists globally for the first time.